Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma.
暂无分享,去创建一个
P. Mclaughlin | F. Cabanillas | F. Cabanillas | M. Keating | A. Sarris | F. Hagemeister | J. Romaguera | O. Pate | A. Younes | F. Swan | Michael J. Keating | Anas Younes | M. Keating | Peter McLaughlin
[1] B. Nathwani,et al. A clinical analysis of two indolent lymphoma entities: mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid B-cell subcategories): a Southwest Oncology Group study. , 1995, Blood.
[2] J. Gribben. Attainment of molecular remission: a worthwhile goal? , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] A. López-Guillermo,et al. Applicability of the International Index for aggressive lymphomas to patients with low-grade lymphoma. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] B. Coiffier,et al. Is the International Prognostic Index for Aggressive Lymphoma patients useful for follicular lymphoma patients? , 1994, Journal of Clinical Oncology.
[5] S. Tucker,et al. ESHAP--an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] P. Mclaughlin,et al. Phase I study of the combination of fludarabine, mitoxantrone, and dexamethasone in low-grade lymphoma. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] M. Fey,et al. High incidence of infections after 2-chlorodeoxyadenosine (2-CDA) therapy in patients with malignant lymphomas and chronic and acute leukaemias. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.
[8] P. Mclaughlin,et al. Intensive conventional-dose chemotherapy for stage IV low-grade lymphoma: high remission rates and reversion to negative of peripheral blood bcl-2 rearrangement. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.
[9] Emili Montserrat,et al. A predictive model for aggressive non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.
[10] E. Estey,et al. Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment. , 1993, Blood.
[11] R. Fanin,et al. Fludarabine: an active agent in the treatment of previously-treated and untreated low-grade non-Hodgkin's lymphoma. , 1993, Annals of oncology : official journal of the European Society for Medical Oncology.
[12] E. Estey,et al. Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent. , 1993, Blood.
[13] P. Wijermans,et al. Severe immunodeficiency in patients treated with fludarabine monophosphate , 1993, European journal of haematology.
[14] John Calvin Reed,et al. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. , 1993, Blood.
[15] M. Story,et al. Induction of apoptotic cell death in chronic lymphocytic leukemia by 2-chloro-2′-deoxyadenosine and 9-β-D-arabinosyl-2-fluoroadenine , 1993 .
[16] E. Estey,et al. Nucleoside analogs in treatment of chronic lymphocytic leukemia. , 1993, Leukemia & lymphoma.
[17] B. Cheson. New antimetabolites in the treatment of human malignancies. , 1992, Seminars in oncology.
[18] B. Barlogie,et al. Primary dexamethasone treatment of multiple myeloma. , 1992, Blood.
[19] M. Oken,et al. Survival after relapse of low-grade non-Hodgkin's lymphoma: implications for marrow transplantation. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] W. Velasquez,et al. Phase II trial of fludarabine phosphate in lymphoma: an effective new agent in low-grade lymphoma. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] M. Oken,et al. Activity of fludarabine in previously treated non-Hodgkin's low-grade lymphoma: results of an Eastern Cooperative Oncology Group study. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] T. Miller,et al. Multicenter clinical trial of mitoxantrone in non-Hodgkin's lymphoma and Hodgkin's disease. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] R. Schreiber,et al. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death , 1990, Nature.
[24] S. Tucker,et al. A new serologic staging system for large-cell lymphomas based on initial beta 2-microglobulin and lactate dehydrogenase levels. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] E. Gehan,et al. Reporting outcomes in Hodgkin's disease and lymphoma. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] M. Grever,et al. Phase II trial of 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate in non-Hodgkin's lymphoma: prospective comparison of response with deoxycytidine kinase activity. , 1987, Cancer research.
[27] R. Fisher,et al. Excess prevalence of Pneumocystis carinii pneumonia in patients treated for lymphoma with combination chemotherapy. , 1986, Annals of internal medicine.
[28] Portlock Cs. Deferral of initial therapy for advanced indolent lymphomas. , 1982 .
[29] S. Ostrow,et al. Nodular lymphoma. Prolongation of survival by complete remission. , 1981, Cancer clinical trials.
[30] R. S. Williams,et al. Clinical and radiologic remission in reticulum cell sarcoma of the brain. , 1979, Archives of neurology.